Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H, M, R | WB | Rb | Purified | Polyclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | 07-606 |
| Replaces | 04-1098 |
| Brand Family | Upstate |
| Trade Name |
|
| Description | Anti-phospho-JAK2 (Tyr1007/1008) Antibody |
| Alternate Names |
|
| Background Information | JAK2 (Janus Kinase 2) belongs to the emerging family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to CIS elements upstream of target gene promoters to regulate transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor. Among a variety of sites, Tyrosines 1007 and 1008 are sites of trans- or autophosphorylation in vivo and in in vitro kinase reactions. |
| Product Information | |
|---|---|
| Format | Purified |
| Control |
|
| Presentation | Purified rabbit IgG in buffer containing 0.1M Tris-Glycine, 0.15M NaCl, 0.05% Sodium Azide, pH7.4. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Anti-phospho-JAK2 (Tyr1007/1008) Antibody detects level of phospho-JAK2 (Tyr1007/1008) & has been published & validated for use in WB. |
| Key Applications |
|
| Biological Information | |
|---|---|
| Immunogen | KLH-conjugated, synthetic peptide corresponding to amino acids surrounding phosphotyrosines 1007 and 1008 of human JAK2. |
| Epitope | Tyr1007/1008 |
| Concentration | Please refer to the Certificate of Analysis for the lot-specific concentration. |
| Host | Rabbit |
| Specificity | Recognizes phosphorylated JAK2, Mr 130 kDa. |
| Isotype | IgG |
| Species Reactivity |
|
| Species Reactivity Note | Human and mouse. Predicted to cross-react with rat based on sequence homology. |
| Antibody Type | Polyclonal Antibody |
| Entrez Gene Number |
|
| Entrez Gene Summary | This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. |
| Gene Symbol |
|
| Modifications |
|
| Purification Method | Protein A Purfied |
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: O60674 # Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction. SIZE: 1132 amino acids; 130674 Da SUBUNIT: Interacts with SIRPA (By similarity). Interacts with IL23R, SKB1 and STAM2. SUBCELLULAR LOCATION: Intracytoplasmic membrane; Peripheral membrane protein (By similarity). Note=Wholly intracellular, possibly membrane associated (By similarity). TISSUE SPECIFICITY: Expressed in blood, bone marrow and lymph node. DOMAIN: SwissProt: O60674 Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1. DISEASE: SwissProt: O60674 # Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6. & Defects in JAK2 are a cause of susceptibility to Budd- Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites. & Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients. & Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications. & Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension. & Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily. & Contains 1 FERM domain. & Contains 1 protein kinase domain. & Contains 1 SH2 domain. |
| Molecular Weight | 130 kDa |
| Product Usage Statements | |
|---|---|
| Quality Assurance | Routinely evaluated by Western Blot on Pervanadate treated L6 lysates. Western Blot Analysis: 1:500 dilution of this lot detected PHOS-JAK2 (TYR1007/1008) on 10 ug of Pervanadate treated L6 lysates. |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable for 1 year at 2-8°C from date of receipt. For maximum recovery of product, centrifuge the original vial prior to removing the cap. |
| Packaging Information | |
|---|---|
| Material Size | 200 µg |